Veradermics Financial Statements
NYSE: MANEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
130.90+4.27 (+3.37%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 130.90 +0.19%
Veradermics revenue and earnings
Veradermics reported a net loss of $70.0 million, compared with a loss of $26.5 million a year earlier. Diluted earnings per share came in at -$111.91.
Summary generated from market data by MetaCap's automated system. Methodology
Veradermics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 |
|---|---|---|
| Operating Expenses | 72.35M | 26.78M |
| Research & Development | 62.06M | 23.28M |
| Operating Income | -72.35M | -26.78M |
| Interest Expense | 0 | 585.00K |
| Other Income (Expense) | 2.35M | 290.00K |
| Pretax Income | -70.00M | -26.49M |
| Income Tax | 0 | 0 |
| Net Income | -70.00M | -26.49M |
| Net Income growth (YoY) | — | — |
| EPS (Basic) | -111.91 | -37.05 |
| EPS (Diluted) | -111.91 | -37.05 |
| Shares Outstanding (Basic) | 744.99K | 736.93K |
| Shares Outstanding (Diluted) | 744.99K | 736.93K |
This table shows 2 annual periods of Veradermics's income statement, from FY 2025 back to FY 2024, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow MANE's reporting calendar. What is a income statement?